No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review.

J Bone Joint Surg Am · 2026 · PMC13127733 · PMID 41921052

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

approached significancep = 0.05actually significant

At the 2-year follow-up in the 3-cohort study on THA, the difference in component revision rates approached significance (p = 0.05), favoring GLP-1 RA users (<2.3%) over severely obese patients (3.9%) and morbidly obese non-users (3.1%) 32 .

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.